Press Release

Viral Vector Production Market to grow with a CAGR of 15.45% through 2030

Rising Prevalence of Genetic Disorders is the major drivers for the Global Viral Vector Production Market growth in the forecast period, 2026-2030.


According to TechSci Research report, “Viral Vector Production Market - Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, Global Viral Vector Production Market stood at USD 6.71 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 15.45% through 2030. The Global Viral Vector Production Market is anticipated to register a high CAGR during the forecast period. This can be ascribed to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

The rising prevalence of genetic disorders is significantly driving the demand for viral vector production globally. Genetic conditions like cystic fibrosis, hemophilia, and muscular dystrophy often lack curative treatments, prompting a surge in gene therapy research. Viral vectors serve as the backbone of these therapies by delivering corrected genes to affected cells, positioning them as essential tools in modern medical interventions.

As awareness and diagnosis of genetic disorders improve, the need for advanced, targeted therapies continues to grow. Viral vectors offer a promising avenue due to their ability to efficiently and specifically deliver therapeutic genes. This has fueled investments in vector development, pushing biopharmaceutical companies and research institutions to expand production capacity to meet the growing clinical demand.

Furthermore, the rise in newborn screening programs and genetic testing has led to early detection of many inherited conditions. This proactive healthcare approach increases the urgency for effective treatments, boosting the adoption of viral vector-based solutions. As a result, the viral vector production market is witnessing sustained momentum, driven by the need to support a growing pipeline of gene therapy candidates.


Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Viral Vector Production Market



The Global Viral Vector Production Market segmentation is based on Vector Type, Workflow, Application, End User, By Company, and Region.

Based on vector type, Adeno-Associated Virus (AAV) vectors are growing swiftly in the viral vector production market due to their favorable safety and efficacy profile. AAV vectors are non-pathogenic, exhibit low immunogenicity, and offer long-term gene expression, making them ideal for gene therapy applications. Their ability to target both dividing and non-dividing cells enhances their therapeutic potential across a wide range of genetic disorders, including neurological and ocular diseases. Additionally, advancements in AAV engineering have improved tissue specificity and transduction efficiency. With several AAV-based therapies receiving regulatory approvals and many more in the pipeline, the demand for AAV vectors continues to accelerate globally.

Based on region, Asia-Pacific is growing exponentially in the viral vector production market due to increasing investments in biotechnology, expanding gene therapy research, and supportive government initiatives. Countries like China, Japan, South Korea, and India are rapidly building biomanufacturing infrastructure and fostering innovation in cell and gene therapies. Additionally, rising awareness, improved healthcare access, and growing patient populations with genetic disorders are accelerating demand. Regional collaborations between academic institutions and biotech firms are further boosting clinical trial activity and production capacity. As regulatory frameworks mature and local capabilities strengthen, Asia-Pacific is becoming a key hub for cost-effective and scalable viral vector manufacturing.


Some of the major companies operating in the United Global Viral Vector Production Market include:

  • Merck kgaa
  • FUJIFILM Diosynth Biotechnologies U.S.A
  • Cobra Biologics Ltd.
  • Thermofisher Scientific Inc.
  • Waisman Biomanufacturing
  • Genezen Laboratories
  • Advanced BioScience Laboratories, Inc. (ABL inc.)
  • Novasep Holding s.a.s.
  • Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
  • Takara Bio Inc. 

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.


“Certain areas, particularly in the Northeast, are projected to exert significant demand for Viral Vector globally. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Viral Vector Production Market in the forecast period," said Mr. Karan Chechi, Research Director of TechSci Research, a research-based Global management consulting firm.

"Viral Vector Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vector Type (Adenovirus, AAV, Lentivirus, Retrovirus, others), By Workflow (Upstream Processing, Vector amplification and expansion, Vector recovery/harvesting, Downstream Processing, Purification, Fill finish), By Application (Gene and Cell Therapy Development, Vaccine Development, Biopharmaceutical and Pharmaceutical Discovery, Biomedical Research), By End User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes), By Region and Competition, 2020-2030F", has evaluated the future growth potential of Global Viral Vector Production Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Viral Vector Production Market.


Contact

TechSci Research LLC                                                                                              

420 Lexington Avenue, Suite 300,

New York, United States- 10170

M: +13322586602

Email: [email protected]

Web:  https://www.techsciresearch.com

Relevant News